Evaluation of copper-labeled bifunctional chelate-albumin conjugates for blood pool imaging
References (11)
- et al.
Synthesis and evaluation of a new bifunctional chelating agent for 99mTc labeling proteins: p-carboxyethylphenylglyoxal(N-methylthiosemicarbazone)
Nucl. Med. Biol.
(1986) - et al.
Serum stability of 67Cu chelates: comparison with 111In and 57Co
Nucl. Med. Biol.
(1986) - et al.
The preparation and labeling of DTPA-coupled albumin
Int. J. Appl. Radiat. Isot.
(1982) - et al.
Copper chelates as probes of biological systems: stable copper complexes with a macrocyclic bifunctional chelating agent
Analyt. Biochem.
(1985) A centrifuged column procedure for the measurement of ligand binding by beef heart ATPase
There are more references available in the full text version of this article.
Cited by (24)
[<sup>64</sup>Cu]diacetyl-bis(N<sup>4</sup>-methyl-thiosemicarbazone) - a radiotracer for tumor hypoxia
2008, Nuclear Medicine and BiologyNew modulated metallic macrocycles: Electrochemistry and their interaction with calf thymus DNA
2005, Acta BiomaterialiaGallium-68-DOTA-albumin as a PET blood-pool marker: Experimental evaluation in vivo
2005, Nuclear Medicine and BiologyIn vivo evaluation of copper-64-labeled monooxo-tetraazamacrocyclic ligands
2004, Nuclear Medicine and BiologyProduction and applications of copper-64 radiopharmaceuticals
2004, Methods in EnzymologyCitation Excerpt :For ligands of the polyamine system, the macrocyclic chelators are more topologically constrained than the acyclic ones because of the absence of “head” and “end” groups in a ring,38 which provides the copper macrocyclic complexes with extra kinetic stability and thermodynamic stability as well. This is the reason why macrocyclic chelators have historically been used as BFCs to bind 67Cu(II) to antibodies rather than acyclic chelators such as ethylenediaminetetraacetic acid (EDTA) and diethylenetetraaminepentaacetic acid (DTPA).32,39–41 Currently, the application of 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (TETA) as a BFC for copper radiopharmaceuticals has advanced to clinic trials.42,43
Copper radionuclides and radiopharmaceuticals in nuclear medicine
1996, Nuclear Medicine and Biology
Copyright © 1993 Published by Elsevier Inc.